ArticleMolecular oncology2019
Single-cell RNA-seq reveals the invasive trajectory and molecular cascades underlying glioblastoma progression.
Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Review
- Competing endogenous RNA networks in ovarian cancer: from bench to bedside.EXCLI journal · 2025Review
- Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.Nature communications · 2024Article
- Spatial Transcriptomics in a Case of Follicular Thyroid Carcinoma Reveals Clone-Specific Dysregulation of Genes Regulating Extracellular Matrix in the Invading Front.Endocrine pathology · 2024Article
- uPAR (PLAUR) Marks Two Intra-Tumoral Subtypes of Glioblastoma: Insights from Single-Cell RNA Sequencing.International journal of molecular sciences · 2024Article
- Spatial metabolic heterogeneity of oligodendrogliomas at single-cell resolution.Brain tumor pathology · 2023Article
- Quantitative Evaluation of Stem-like Markers of Human Glioblastoma Using Single-Cell RNA Sequencing Datasets.Cancers · 2023Article
- Molecular targeted therapy: A new avenue in glioblastoma treatment.Oncology letters · 2023Review
- RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.Frontiers in immunology · 2023Article
- A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories.Stem cells international · 2023Article
- Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival.Nature communications · 2022Article
- Single-cell transcriptome highlights a multilayer regulatory network on an invasive trajectory within colorectal cancer progression.Journal of cancer research and clinical oncology · 2022Article
- Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.Advanced drug delivery reviews · 2022Review
- Clinical Characterization and Prognostic Value of TPM4 and Its Correlation with Epithelial-Mesenchymal Transition in Glioma.Brain sciences · 2022Article
- Article
- Identification of hub genes and transcription factor regulatory network for heart failure using RNA-seq data and robust rank aggregation analysis.Frontiers in cardiovascular medicine · 2022Article
- Intercellular Communication-Related Molecular Subtypes and a Gene Signature Identified by the Single-Cell RNA Sequencing Combined with a Transcriptomic Analysis.Disease markers · 2022Article
- Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy.Frontiers in immunology · 2022Article
- Bioinformatic profiling identifies the glutaminase to be a potential novel cuproptosis-related biomarker for glioma.Frontiers in cell and developmental biology · 2022Article
- A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.Cellular oncology (Dordrecht, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, in which GBM stem cells (GSCs) were identified to contribute to aggressive phenotypes and poor prognosis. Yet, how GSCs progress to invasive cells remains largely unexplored. Here, we revealed the cell subpopulations with distinct functional status and the existence of cells with high invasive potential within heterogeneous primary GBM tumors. We reconstructed a branched trajectory by pseudotemporal ordering of single tumor cells, in which the root showed GSC-like phenotype while the end displayed high invasive activity. Thus, we further determined a path along which GSCs gradually transformed to invasive cells, called the 'stem-to-invasion path'. Along this path, cells showed incremental expression of GBM invasion-associated signatures and diminishing expression of GBM stem cell markers. These findings were validated in an independent single-cell data set of GBM. Through analyzing the molecular cascades underlying the path, we identify crucial factors controlling the attainment of invasive potential of tumor cells, including transcription factors and long noncoding RNAs. Our work provides novel insights into GBM progression, especially the attainment of invasive potential in primary tumor cells, and supports the cancer stem cell model, with valuable implications for GBM therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.